CO6470830A2 - PHARMACEUTICAL FORM OF SUSTAINED RELEASE - Google Patents

PHARMACEUTICAL FORM OF SUSTAINED RELEASE

Info

Publication number
CO6470830A2
CO6470830A2 CO11161975A CO11161975A CO6470830A2 CO 6470830 A2 CO6470830 A2 CO 6470830A2 CO 11161975 A CO11161975 A CO 11161975A CO 11161975 A CO11161975 A CO 11161975A CO 6470830 A2 CO6470830 A2 CO 6470830A2
Authority
CO
Colombia
Prior art keywords
semi
pharmaceutical form
permeable membrane
sustained release
membrane
Prior art date
Application number
CO11161975A
Other languages
Spanish (es)
Inventor
Dayu Zhai
Robert L Schmitt
Alan Ka Chun Chan
Yong Gan
Chunliu Zhu
Original Assignee
Dow Global Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Llc filed Critical Dow Global Technologies Llc
Priority to CO11161975A priority Critical patent/CO6470830A2/en
Publication of CO6470830A2 publication Critical patent/CO6470830A2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Una forma farmacéutica osmótica que consta de: (a) un núcleo que contiene un ingrediente biológicamente activo; (b) una membrana semipermeable que cubre el citado núcleo; y (c) por lo menos un conducto a través de la membrana semipermeable, en donde la membrana semi-permeable contiene etil celulosa, un polímero acrílico o metacrílico y un plastificante soluble en agua, con la condición que la membrana semi-permeable no contenga o contenga no más de 15 por ciento en peso de un material soluble en agua, excluyendo cualquier plastificante soluble en agua, basado en el peso total seco de la membrana semi-permeable.An osmotic pharmaceutical form consisting of: (a) a nucleus that contains a biologically active ingredient; (b) a semipermeable membrane that covers said core; and (c) at least one conduit through the semipermeable membrane, wherein the semi-permeable membrane contains ethyl cellulose, an acrylic or methacrylic polymer and a water-soluble plasticizer, provided that the semi-permeable membrane does not contain or contains no more than 15 percent by weight of a water soluble material, excluding any water soluble plasticizer, based on the total dry weight of the semi-permeable membrane.

CO11161975A 2011-11-25 2011-11-25 PHARMACEUTICAL FORM OF SUSTAINED RELEASE CO6470830A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CO11161975A CO6470830A2 (en) 2011-11-25 2011-11-25 PHARMACEUTICAL FORM OF SUSTAINED RELEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO11161975A CO6470830A2 (en) 2011-11-25 2011-11-25 PHARMACEUTICAL FORM OF SUSTAINED RELEASE

Publications (1)

Publication Number Publication Date
CO6470830A2 true CO6470830A2 (en) 2012-06-29

Family

ID=46940763

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11161975A CO6470830A2 (en) 2011-11-25 2011-11-25 PHARMACEUTICAL FORM OF SUSTAINED RELEASE

Country Status (1)

Country Link
CO (1) CO6470830A2 (en)

Similar Documents

Publication Publication Date Title
NL301256I2 (en) cedazuridine, or a pharmaceutically acceptable salt thereof
NL300886I2 (en) baricitinib, or a pharmaceutically acceptable salt thereof
NO2016016I1 (en) Lesinurad, or a pharmaceutically acceptable salt thereof
CL2013002496A1 (en) Artificial grass system comprising a carpet material, a plurality of fibers that extend from the carpet material, and a receiving material disposed on the carpet material between the individual fibers, where the shell includes fire retardant pellets.
AR089268A1 (en) WATER COMPOSITIONS FOR ORAL CARE
RS54873B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
BR112015011163A2 (en) thermoplastic membranes containing expandable graphite
IT1402901B1 (en) MODULAR STRUCTURE, PARTICULARLY FOR BUILDING.
PE20110927A1 (en) PHARMACEUTICAL DOSAGE FORM INCLUDING NIFEDIPINE OR NISOLPINE AND AN ANGIOTENSIN II ANTAGONIST
JP2011175111A5 (en)
UY34107A (en) PESTICIDE MIXTURES THAT INCLUDE ISOXAZOLINIC DERIVATIVES; METHOD FOR CONTROLLING INSECTS, ACARIDS, NEMATODES OR MOLLUSCS AND METHOD FOR COVERING A SEED ?.
CR20140334A (en) DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE
BRPI1015443A2 (en) "a modular storage system."
CL2014001318A1 (en) Absorbent article comprising an absorbent core having a dry thickness at the crotch point of the article of 0.2 to 5 mm, wherein one or more portions of the absorbent structure contains at least 90% by weight of superabsorbent polymer particles .
GT201200304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
RS54238B1 (en) Oral film formulations comprising dapoxetine and tadalafil
RS54158B1 (en) Amyloid binding agents
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
JP2013541099A5 (en)
AR067018A1 (en) INHALER
CL2012003341A1 (en) Pharmaceutical composition for oral administration comprising bendamustine or an ester, a salt or a solvate thereof, and an excipient which is a non-ionic and hydrophilic surfactant; pharmaceutical combination; and its use for the treatment of chronic lymphocytic leukemia and multiple myeloma, among other diseases.
ES2660019T3 (en) Patch containing diclofenac and thiocolchicose
ECSP099386A (en) AGENTS TO FIGHT PARASITES IN ANIMALS
NI201400065A (en) PREPARATIONS INCLUDING AMORPHOUS EMODEPSIDE
NL1036370A1 (en) Modular buildable storage system for pipes.

Legal Events

Date Code Title Description
FC Application refused